Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2017BloodOpen Access

Role of RUNX1 in hematological malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRaman SoodNational Institutes of HealthYKYasuhiko KamikuboKyoto UniversityPLPaul LiuNational Human Genome Research Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sood et al. (2017) studied this question.

synapsesocial.com/papers/6a09eeb4818b42a7b433f034https://doi.org/10.1182/blood-2016-10-687830
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Familial Defect in Platelet Function Associated with Impaired Release of Adenosine Diphosphate1969 · 127 citations
  2. 2Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.1993 · 229 citations
  3. 3RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures2012 · 271 citations
  4. 4Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction2012 · 139 citations
  5. 5A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies2001 · 135 citations